Trial Profile
Phase I Trial of Radiation Therapy Plus Temozolomide With MK-3475 in Patients With Newly Diagnosed Glioblastoma (GBM)
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 21 Nov 2023
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary) ; Temozolomide
- Indications Glioblastoma
- Focus Adverse reactions
- 16 Nov 2023 Status changed from active, no longer recruiting to discontinued.
- 13 Nov 2023 Planned End Date changed from 1 Nov 2020 to 11 Oct 2024.
- 13 Nov 2023 Status changed from discontinued to active, no longer recruiting.